

## [<sup>68</sup>Ga]Ga-AntiCAD1: Radiosynthesis and First Imaging Study on Rats

Burcu UCAR<sup>1,2,a</sup> Tayfun ACAR<sup>1,b</sup> Pelin PELİT ARAYICI<sup>1</sup>  
Zeynep MUSTAFAEVA<sup>1</sup> Mehmet Onur DEMİRKOL<sup>2,3</sup>

<sup>1</sup>Yıldız Technical University, Chemical and Metallurgical Engineering Faculty, Bioengineering Department, TR-34210 Istanbul - TURKEY

<sup>2</sup>VKF American Hospital, Department of Nuclear Medicine and Molecular Imaging, TR-34365 Istanbul - TURKEY

<sup>3</sup>Koc University, School of Medicine, Department of Nuclear Medicine and Molecular Imaging, TR-34010 Istanbul - TURKEY

<sup>a</sup> ORCID:0000-0002-8540-7832; <sup>b</sup> ORCID:0000-0001-5006-8167

Article Code: KVFD-2018-19487 Received: 23.01.2018 Accepted: 09.05.2018 Published Online: 10.05.2018

### How to Cite This Article

Ucar B, Acar T, Pelit Arayıcı P, Mustafaeva Z, Demirkol MO: [<sup>68</sup>Ga]Ga-AntiCAD1: Radiosynthesis and first imaging study on rats. *Kafkas Univ Vet Fak Derg*, 24 (4): 531-538, 2018. DOI: 10.9775/kvfd.2018.19487

### Abstract

Cadherins are cell adhesion and cell signaling molecules that provide the molecular link between each adjacent cells and have critical importance for the initiation and continuation of adhesion mechanism. N-cadherin expression provides a correlation between upregulation of N-cadherin and inflammation of the lesions. In this paper, we concentrated on the radiolabeling and evaluation of [<sup>68</sup>Ga]Ga-AntiCAD1 agent as a potential candidate for *in vivo* PET/CT imaging of adhesions. The synthetic N-Ac-CHAVC-NH<sub>2</sub> cyclic peptide sequence designed as (ADH-1)c containing the selective binding His-Ala-Val (HAV) motif based on the chimeric antigen receptor sequence acts as the N-cadherin antagonist. In our previous study, AntiCAD1 conjugate has been studied in detail which is in the process of publication. In this study, the conjugate was radiolabelled with the [<sup>68</sup>Ga]Ga radionuclide eluted from the <sup>68</sup>Ge/<sup>68</sup>Ga generator (IDB Holland). Radiochemical purity of [<sup>68</sup>Ga]Ga-AntiCAD1 agent was analysed with TLC methods. The 'shake-flask' method was applied to determine lipophilicity of the agent by calculating the P distribution coefficient (logP=-2.69±0.54). The biodistribution of the agent was investigated using PET/CT on Wistar Albino rats. Significant uptake was found in liver, kidneys, spleen, salivary gland and targeted region with SUV<sub>max-mean</sub> of 1.36, 1.96, 1.38, 1.16 and 2.14 respectively. The Pearson Factorial method is used to test the relationship between the targeted region and other body tissues, to measure the degree of this relationship (R=0.73). Radiolabelled agent was demonstrated to react specifically with N-cadherin in targeting of rat tissues.

**Keywords:** AntiCAD1 agent, Peptide radiopharmaceuticals, PET/CT imaging, N-cadherin expression

## [<sup>68</sup>Ga]Ga-AntiCAD1: Radyosentez ve Sıçanlar Üzerinde İlk Görüntüleme Çalışması

### Öz

Kadherinler, bitişik hücreler arasındaki moleküler bağlantıyı sağlayan, yapışma mekanizmasının başlatılması ve devamı için kritik öneme sahip olan hücre adezyon ve hücre sinyal molekülleridir. N-kadherin ekspresyonu, N-kadherinin artışı ve lezyonların inflamasyonu arasında bir korelasyon sağlar. Bu makalede, adezyonların *in vivo* PET/CT görüntülenmesi için potansiyel bir aday olarak [<sup>68</sup>Ga]Ga-AntiCAD1 ajanının radyoşaretlenmesi ve değerlendirmesine odaklanılmıştır. Kimerik antijen reseptörü dizisine dayanan seçici bağlayıcı His-Ala-Val (HAV) motifini içeren (ADH-1)c olarak tasarlanan sentetik N-Ac-CHAVC-NH<sub>2</sub> siklik peptid dizisi, N-kadherin antagonisti olarak işlev görür. Yayın aşamasındaki önceki çalışmamızda AntiCAD1 konjugatı ayrıntılı olarak incelenmiştir. Bu çalışmamızda, konjugat, <sup>68</sup>Ge/<sup>68</sup>Ga jeneratöründen (IDB Holland) elde edilen [<sup>68</sup>Ga]Ga radyonüklidi ile radyoaktif olarak işaretlendi. [<sup>68</sup>Ga]Ga-AntiCAD1 ajanının radyokimyasal saflığı TLC metodları ile analiz edildi. Ajanın lipofilitesini belirlemek için P dağılım katsayısı hesaplanarak 'çalkalama şişesi' yöntemi uygulandı (logP=-2.69±0.54). Ajanın biyodağılımı, Wistar Albino sıçanları üzerinde PET/CT kullanılarak araştırıldı. Karaciğer, böbrekler, dalak, tükürük bezi ve hedef bölgede sırasıyla ortalama 1.36, 1.96, 1.38, 1.16 ve 2.14 SUV<sub>max</sub> değerleri ile kayda değer oranda tutulum tespit edildi. Hedeflenen bölge ile diğer vücut dokuları arasında olan ilişkini test etmek ve bu ilişkinin derecesini ölçmek için istatistiksel Pearson Faktörü hesaplama yöntemi kullanılmıştır (R=0.73). Sıçan dokularının hedeflenmesinde radyoşaretli ajanın N-kadherin ile spesifik olarak etkileşime girdiği gösterildi.

**Anahtar sözcükler:** AntiCAD1 ajanı, Peptid radyofarmasötikleri, PET/CT görüntüleme, N-kadherin ekspresyonu



### İletişim (Correspondence)



+90 212 3112000/4926



[burcuu@amerikanhastanesi.org](mailto:burcuu@amerikanhastanesi.org)

## INTRODUCTION

Cadherins are cell surface glycoproteins responsible for morphogenesis in the embryo, selective cell recognition in the adult organism, and lifelong normal tissue architecture. Adherens junctions which are essential for the formation and maintenance of functional cellular junctions are composed of cadherins [1]. Cadherins are cell adhesion and cell signaling molecules that provide the molecular link between adjacent cells and have critical importance for the initiation and continuation of adhesion mechanism. It differs from the other members of the cadherin group compounds with a large extracellular N-terminal consisting of repeating domains and important Ca<sup>++</sup> binding, and a single transmembrane region linked to the cytoplasmic region. N (Neural)-cadherin is presented in mesenchymal tissues, in endothelial cells and found in adhesive complexes that cover them between endothelial cells and pericytes [2-4]. N-cadherin antagonists which are expressed in some tumor cells and blood vessels target N-cadherin. The re-expression of N-cadherin in endothelial cells is accompanied by neovascularization. There was a correlation between upregulation of N-cadherin and inflammation events by indicating it in the enlarged blood vessels of the inflamed tissue of the lesions [5]. It has been shown that the synthetic N-Ac-CHAVC-NH<sub>2</sub> cyclic peptide sequence designed as ADH-1 which contains the selective binding HAV (His-Ala-Val) motif based on the CAR(Chimeric Antigen Receptors) sequence acts as the N-cadherin antagonist [6]. Cyclic (ADH-1)c peptide analogue has the ability to disrupt many processes through N-cadherin, as well as the linear peptide [7]. There are studies on targeting of N-cadherin expression in order to understand the mechanism of many different cancer types and the functions of proximal renal tubular epithelial cells [8-10]. In this study, AntiCAD1 agent was targeted to the N-cadherin receptor in epithelial tissue adhesion. The data based on the positron emission tomographic imaging-computed tomography (PET/CT) which is the 'gold standard' in imaging was obtained by the combination of metabolic chemical activity of the agent and anatomic information in rat organism. PET imaging provides detailed information about the results of metabolic activities and cellular functions. Peptides labelled with a positron-emitting radionuclide can be used to make an accurate diagnosis, determine staging and quantify the radiation dose to tumors and critical organs, thus allowing dose planning and dose monitoring for successful radiotherapy, and to follow target response to therapy, thus providing personalized patient management [11-13]. The compatibility of [<sup>68</sup>Ga]Ga with peptides for targeted imaging of such receptors as somatostatin, bombesin, human epidermal growth factor, integrin, vascular endothelial growth factor, cholecystokinin-2, gastrin-releasing peptide, melanocyte stimulation hormone, glucagon-like peptide 1, gonadotropin-releasing hormone, folate, neurotensin, and neuropeptide Y receptors has been demonstrated [12,13].

The corresponding ligands commonly have satisfactory pharmacokinetics with fast blood clearance, relatively low hepatobiliary excretion, and mostly renal elimination as well as excellent tissue penetration, minimal side-effects, and no or low antigenicity. Imaging of vascular endothelial growth factor (VEGF) receptors overexpressed in tumors, adhesive and violated tissues (by injury or surgical intervention) that have extensive formation of new capillaries is an important means not only for diagnosis and monitoring response therapy but also for antiangiogenic drug development.

## MATERIAL and METHODS

The cyclic (ADH-1)c peptide analogue was obtained in our laboratory with using CEM Liberty microwave assisted automatic peptide synthesis system and applying cyclization procedure, respectively. EDC [1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride], EDTA (Ethylenediaminetetraacetic acid) and all other chemicals purchased from Sigma Aldrich Chemicals (St. Louis), USA. Ultra-pure water was obtained from Millipore Milli-Q system.

Koc University National Ethics Committee for Animal Experiments gave approval for the animal experiments (Protocol no: 2016.HADYEK.018, 02/06/2016 dated).

### Preparation of Cyclic (ADH-1)c Peptide-EDTA Conjugate

Peptide synthesis and conjugation with EDTA have been studied in detail in our previous study, which is in the process of publication. Briefly, the linear ADH-1 peptide sequence (Ac-Cys-His-Ala-Val-Cys-CONH<sub>2</sub>) was synthesized using the Fmoc chemistry in the CEM Liberty Microwave Assisted Solid Phase Peptide Synthesis System. The peptide precipitated as a white powder was stored at -18°C for cyclization [14-16]. The cyclization process is based on the procedure described by Dubey et al. [17]. A disulfide bridge was formed between the two cysteines by oxidation of the thiol groups of the cysteine residues. After the process was complete, the cyclic peptide was lyophilized [17]. Conjugate of the cyclic (ADH-1)c peptide with EDTA chelator was synthesized by the water-soluble carbodiimide procedure in the presence of the EDC crosslinker [18-20]. LC-MS m/z for cyclic(ADH-1)c peptide [M+H]<sup>+</sup>=572.85 and EDTA-(ADH-1)c conjugate (AntiCAD1 conjugate) [M+H]<sup>+</sup>=867.

### Elution of <sup>68</sup>Ge/<sup>68</sup>Ga Generator

The <sup>68</sup>Ga radionuclide (t<sub>1/2</sub> = 67.7 min., β<sup>+</sup> = 89%, E β<sup>+</sup> maks, 1.9 MeV, EC: 11%, E<sub>γ</sub> maks: 4.0 MeV) was manually eluted from the SnO<sub>2</sub>-based <sup>68</sup>Ge/<sup>68</sup>Ga generator (IDB Holland iThemba Lab. Generator, 30mCi) using a disposable syringe with 15 mL of 0.6 M HCl acid and collected into a vial containing 1 mL of 9.5 M HCl acid. The resulting <sup>68</sup>Ga solution was subjected to cationic pre-purification to bring it to levels that would allow labeling with

peptides. Approximately 1.5 mL of 15 mCi [ $^{68}\text{Ga}$ ]Ga was obtained.

### Radiolabelling of AntiCAD1 Conjugate with [ $^{68}\text{Ga}$ ]Ga Radionuclide

To carry out the labeling with the [ $^{68}\text{Ga}$ ]Ga radionuclide eluted from the  $^{68}\text{Ge}/^{68}\text{Ga}$  generator, after transferring the 30  $\mu\text{L}$  AntiCAD1 conjugate to the reaction vial, 1.5  $\mu\text{M}$  HEPES buffer was added and pH adjusted to 4. Immediately thereafter, 1.5 mL of eluted [ $^{68}\text{Ga}$ ]Ga was added and the reaction was carried out in a microwave oven under nitrogen and dry air atmosphere at 125 degrees centigrade for 6 min. At the end of the reaction, the radiopharmaceutical labeling rate of the product (Fig. 1) was evaluated by adding 15 mL of PBS buffer to the reaction vial.

### TLC for Radiochemical Purity Analysis of [ $^{68}\text{Ga}$ ]Ga-AntiCAD1 Agent

Product purity was analyzed by TLC on iTLC-SG plates: Labeling rate of [ $^{68}\text{Ga}$ ]Ga-AntiCAD1 agent were studied with three different mobile phase solutions [Solution A; Isopropil alcohol:n-butanol:0.2 N ammonium hydroksit (2:1:1 (v:v:v)), Solution B; n-butanol:water:acetic acid(4:2:1 (v:v:v)) and Solution C; TFA 0.1%:MeOH (30:70 (v:v))]. Solution A, B and C were added to the chromatography tanks. Ten  $\mu\text{L}$  of the synthesized product was dropped onto

the sample spot in the start line of each chromatographic strip. The solutions were run to solvent line. Each strip was allowed to dry at room temperature. The drying strips were cut to equal lengths. The activity value of each piece was read in a gamma counter (Biodex, Atom Lab 500).

Rf and dose values were calculated for each parts. Quantitative analysis of radioactive spots were done to determine the amount of radiolabelled agent and unchelated radiometal [21,22].

### Lipophilicity

Lipophilicity to drug development is an important early indicator of potential *in vivo* pharmacokinetic and dynamic behavior. Lipophilicity measurements provide information on non-specific binding, metabolic stability, drug distribution and excretion [23,24]. Because of this diversity, lipophilicity is one of the most important physicochemical properties and most frequently analyzed and published parameters [23,25]. The 'shake-flask' method is the 'gold standard' for determining the logP value [25-28]. While lipophilic peptides are excreted through the liver and intestines (hepatobiliary excretion), hydrophilic peptides are primarily excreted through the kidneys (renal excretion). Radiolabeled peptides are usually highly hydrophilic and therefore do not show significant accumulation in the hepatobiliary system. However, peptide lipophilicity is increased by labeling through prosthetic groups [29]. In our study, the shake-flask method was applied to determine lipophilicity. Lipophilicity values were determined by calculating the P distribution coefficient ( $[A]_o/[A]_w$ ). One hundred  $\mu\text{L}$  of the radiolabelled compound was added to the tube containing 3 mL of n-octanol and 3 mL of water. The mixture was stirred with magnetic stirrer for 1 h. It was centrifuged at 3000 rpm for 5 min to completely separate the phases. Activity values were measured in the gama counter by pipetting 500  $\mu\text{L}$  from both phases. LogPvalue was calculated by the logarithm of the ratio between the radioactive counts in the octanol and water fractions.

### Animal Studies

Metabolic functions of the agent applied on Wistar Albino rats were studied with PET/CT (General Electric Healthcare/Discovery 710) and Gama Kamera/SPECT(Siemens) equipped with a low energy, high-resolution collimator under a protocol approved by Koç University Animal Experiments Local Ethics Committee. Rats were fasted for four hours before the each intervention. All interventional and imaging studies were performed under anesthetize by using isoflurane without a vaporizer. The liquid anesthetic was applied to cotton which was




Fig 1. Molecular structure of [ $^{68}\text{Ga}$ ]Ga-AntiCAD1 agent




Fig 2. Rf values of relevant complex region

Substance	Solvent A	Solvent B	Solvent C
$[^{68}\text{Ga}]\text{Ga-AntiCAD1}$	57.14%	64.06%	58.06%
$[^{68}\text{Ga}]\text{Ga-compounds}$	25.71%	35.94%	22.58%

placed in a conical tube for maintenance of anesthesia. Because of the high risk of waste anesthetic gas exposure, this method was performed in a special biosafety cabinet with a carbon filter.

## RESULTS

### Radionuclide Purity Assay with Radio-TLC

Product purity was analyzed by iTLC-SG plates using TLC with three different mobile phases. The Rf values calculated for each activity value read in the gamma counter are shown in Fig. 2. The un-chelated metal also seen in the first part (Rf=0.125) for the three solution types, the second part for solution A and solution B, the fifth part for the solution C and a higher Rf value. The impurities in the solution are migrated to the upper region due to the chemical structure (solubility and polarity) of solution A. The relatively high radioactivity value of the first part in Solution B is due to the fact that solution B has activity in the same part as the un-chelated metal without dragging impurities. The un-chelated metal Rf values and doses measured in the first part in solution A and solution C support each other. The ratios of labelled analytes and unchelated metals are shown in Table 1.

### Scintigraphic and Tomographic Studies


$[^{99}\text{Tc}^m]$ pertechnetate and  $[^{177}\text{Lu}]\text{Lu-PSMA}$  Pre-Imaging Studies with Gamma Camera: Pre-imaging study was

carried out for the purpose of reference imaging. The studies were performed on Wistar Albino rat by using agents which are routinely administered in Nuclear Medicine and Molecular Imaging Department except our new agent. Biodistribution of the new agent in rat tissues and organs can be investigated more sensitively and accurately by using reference imaging. In addition, the amount of dose to be administered to the Wistar Albino rat is determined in advance so that the animal is prevented from overdosing.

Scintigraphic images were obtained from Siemens Gamma Camera/SPECT. Prior to the injection of the radio-pharmaceutical agent,  $[^{99}\text{Tc}^m]$  pertechnetate and  $[^{177}\text{Lu}]\text{Lu-PSMA}$  injections were performed at physiological pH at different times. Many preimages were obtained by the application of intravenous injection of radiolabeled agents to the Wistar Albino rat which uptake and accumulation regions in physiological tissue is previously known.

Gamma camera images were examined at 5<sup>th</sup>, 10<sup>th</sup>, 15<sup>th</sup>, 30<sup>th</sup>, 60<sup>th</sup>, 120<sup>th</sup>, 180<sup>th</sup>, 240<sup>th</sup> min after intraperitoneal injection by using 0.1 mCi pertechnetate. In the first 10 min, stomach uptake, that is the injection site and thyroid uptake, a selective target for the pertechnetate were displayed. At the 15<sup>th</sup> min, the  $[^{99}\text{Tc}^m]$  pertechnetate accumulation in bladder started and after the 120 min the intestinal accumulation was viewed. In this way, thyroid, intestine, stomach and bladder regions were determined in the rats shown in Fig. 3.


Gamma camera images were investigated at 10<sup>th</sup>, 60<sup>th</sup>, 120<sup>th</sup>, 180<sup>th</sup> min and 24<sup>th</sup> h after intravenous injection from the tail vein with 0.1 mCi  $[^{177}\text{Lu}]\text{Lu-PSMA}$  at physiological pH. Fig. 4 indicates that as the injection region tail vein and epididymis-testis region accumulation, right-left kidney uptake and bladder-prostate region accumulation were displayed at the 10<sup>th</sup> min imaging. It is understood from the first hour image that the accumulation in the injection site decreases while uptake increases in the other regions. At the second and third hour's of imaging, left-right kidney uptake which is selective to the prostate-specific membrane agent, and bladder-prostate area accumulation were displayed. At the 24<sup>th</sup> h, right and left kidney uptake was displayed intensely. After all; right-left kidney, urethral continence zone-prostate, testis-epididymis and tail vein regions were determined with  $[^{177}\text{Lu}]\text{Lu-PSMA}$  injection.



**Fig 3.** Gamma camera images at 5<sup>th</sup>, 10<sup>th</sup>, 15<sup>th</sup>, 30<sup>th</sup>, 60<sup>th</sup>, 120<sup>th</sup>, 180<sup>th</sup>, 240<sup>th</sup> min after intraperitoneal injection of rat with using [<sup>99m</sup>Tc<sup>m</sup>] pertechnetate

**PET/CT Adhesion Imaging Studies of [<sup>68</sup>Ga]Ga-AntiCAD1 Agent:** [<sup>68</sup>Ga]Ga-AntiCAD1 consisting of five amino acids was applied to display adhesion molecules in violated tissue via specific binding of bioconjugate to the N-cadherin. The distribution of this agent was studied in the Wistar Albino rat organism by using PET/CT. Tomographic images given in Fig. 5 were obtained from GE Healthcare/Discovery 710 PET/CT. In the study with left hand injured rat as shown in Fig. 6, administration of 0.1 mCi [<sup>68</sup>Ga]Ga-AntiCAD1 at physiological pH was performed by intravenous tailinjection. Increased uptake of the [<sup>68</sup>Ga]Ga-AntiCAD1 agent in the injured adhesive left hand was detected. When PET/CT images of the 1<sup>st</sup> and 3<sup>rd</sup> h were examined besides the intense kidney and bladder uptake as well as synthesized radiopharmaceutical agent there was an expected selective uptake in the targeted region.

**Correlation of PET/CT Standardized Uptake Measurement Values:** The binding specificity was detected with the increased uptake of the [<sup>68</sup>Ga]Ga-AntiCAD1 agent in the injured adhesive left hand. In other tissues the uptake of the agent was low. The statistical method of Pearson Factor was used to test the relationship between the targeted region and other body tissues, to measure the degree of this relationship and to predict similar outcomes. In this way, the degree of linear relationship for all body uptake of two continuous or parametric variables of uptake regions can be calculated. Mean standardized uptake values (SUV)<sub>max-mean</sub> in liver, kidneys, spleen, salivary gland and targeted region were found 1.36, 1.96, 1.38, 1.16 and



**Fig 4.** Gamma camera images at 10<sup>th</sup>, 60<sup>th</sup>, 120<sup>th</sup>, 180<sup>th</sup> minutes and 24 h after intravenous injection of rat with using [<sup>177</sup>Lu]Lu-PSMA


2.14 respectively. The R value was calculated to be 0.7331. This value is in the range of 0.70-0.89, indicating a strong positive correlation.

#### Determination of Lipophilicity

The measured lipophilicity value (log P) of [<sup>68</sup>Ga]Ga-AntiCAD1 was calculated at pH 7 as  $-2.69 \pm 0.54$  (n=3) by the 'shake-flask method'. Minus logP values indicate that the concentration of the labelled compounds in water is higher than its concentration in octanol. This value indicates that the targeted agent is primarily excreted by renal excretion [21,22,30].

## DISCUSSION

The synthesized conjugate was labeled with [<sup>68</sup>Ga]Ga radionuclide which was eluted from the <sup>68</sup>Ge/<sup>68</sup>Ga generator and the product purity was checked by TLC on iTLC-SG plates. The results were found appropriate for



**Fig 5.** PET/CT adhesion image at 60<sup>th</sup> min after intravenous tail injection of rat with using  $[^{68}\text{Ga}]\text{Ga-AntiCAD1}$  agent

**Fig 6.** Left hand injured rat model



animal studies, but the labeling yield could be increased by developing different methods.

Lipophilicity study was performed for *in vitro* evaluation of radiolabelled agent.  $\log P$  values emphasize that excretion is primarily eliminated through the renal clearance. Because of the low lipophilicity of the radiolabelled agent,  $\text{SUV}_{\text{max}}$  value of the kidney uptakes higher in comparison with liver, spleen, and salivary gland uptakes. As a result, theoretical lipophilicity value ( $-2.69 \pm 0.54$ ) was supported with  $\text{SUV}_{\text{max}}$  values [31,32].

Determination of the anatomical location of organs which is essential for animal imaging studies in nuclear medicine is very important in terms of evaluation of the images. The accumulation regions of  $[^{99}\text{Tc}^{\text{m}}]$  and  $[^{177}\text{Lu}]\text{Lu-PSMA}$  are thyroid, intestine, stomach, bladder and salivary gland, kidneys, prostate and liver respectively. The critical organ locations of the animal were fully identified by the uptake of these regions by scintigraphy studies.

PET/CT images were obtained via tail injection of the radiolabelled AntiCAD1 agent. The first and third hours of PET/CT images were analyzed by calculating  $\text{SUV}_{\text{max}}$  within the scope of tomographic study. In this study, we investigated injury-induced disruption of the N-cadherin in adhesive tissue and it was sufficient to maintenance of

functional cellular junctions. The uptakes of the  $[^{68}\text{Ga}]\text{Ga-AntiCAD1}$  agent in the liver, spleen, kidney, salivary gland and adhesive tissue were compared on the basis of  $\text{SUV}_{\text{max}}$  values and the uptake in the targeted region was found to be higher. This result is important for the protection of non-target healthy organs. Radiolabeled agent was demonstrated to react specifically with N-cadherin in targeting of rat tissues or selectively targeted in the injured adhesive tissue. The degree of the linear relationship between the uptake regions and all body uptake was calculated by the Pearson factorial method. The R value (0.7331) indicates that the uptake in the target region correlates with organ uptakes.

Although N-cadherin expression and targeting have been studied, there is no information available about the metabolic chemical activity that results from the specific targeting of this receptor. In this context, PET/CT provides detailed information on metabolic activity and the results of cellular functions. In addition, at this moment injured tissues and focus of infection can not be detected with PET/CT and there is not any common specific PET agent used in the imaging of all solid tumor types. The targeted agent may be a new strong candidate as radiopharmaceutical agent because of its less hepatic uptake than prostate-specific new generation peptidic

agent DKFZ-1007-PSMA, less urine excretion than DCFPyL and through protection feature of healthy tissues<sup>[31]</sup>. As a result, radiolabeled agent derived from the cyclic (ADH-1)c peptide analogue which is an adhesion molecule from cancer epithelial mesenchymal transformation markers may be a potential compound that can be used to discrimination of damaged mesenchymal tissues, determination of metastatic solid tumors and detection of focus of infection by using PET/CT imaging technique.

## ACKNOWLEDGEMENTS

The authors many thank for deceased Prof. Dr. Mamed Mustafaev Akdeste who was the Constitutive Head of the Bioengineering Department of Yildiz Technical University and technician Ismail Sonmez at American Hospital in Nuclear Medicine & Molecular Imaging Department for fruitful ideas in the field of molecular imaging and for providing the excellent tomographic-scintigraphic imaging.

## CONFLICTS OF INTEREST

The authors declare that they have no conflict of interest.

## REFERENCES

- Citi S:** The molecular organization of tight junctions. *J Cell Biol*, 121 (3): 485-489, 1993. DOI: 10.1083/jcb.121.3.485
- Gerhardt H, Wolburg H, Redies C:** N-cadherin mediates pericytic-endothelial interaction during brain angiogenesis in the chicken. *Dev Dyn*, 218 (3): 472-479, 2000. DOI: 10.1002/1097-0177(200007)218:3<472::AID-DVDY1008>3.0.CO;2-#
- Blaschuk OW, Devemy E:** Cadherins as novel targets for anti-cancer therapy. *Eur J Pharmacol*, 625 (1-3): 195-198, 2009. DOI: 10.1016/j.ejphar.2009.05.033
- Fosgerau K, Hoffmann T:** Peptide therapeutics: Current status and future directions. *Drug Discov Today*, 20 (1): 122-128, 2015. DOI: 10.1016/j.drudis.2014.10.003
- Bobryshev YV, Cherian SM, Inder SJ, Lord RSA:** Neovascular expression of VE-cadherin in human atherosclerotic arteries and its relation to intimal inflammation. *Cardiovasc Res*, 43 (4): 1003-1017, 1999. DOI: 10.1016/S0008-6363(99)00125-X
- Blaschuk OW, Gour BJ:** McGill University. Compounds and methods for modulating cell adhesion. Canada US6169071B1. 2006.
- Blaschuk OW, Gour BJ, Farookhi R, Ali A, George S:** Adherex Technologies Inc. Compounds and methods for modulating endothelial cell adhesion. Canada US20060183884A1. 2003.
- Mariotti A, Perotti A, Sessa C, Rüegg C:** N-cadherin as a therapeutic target in cancer. *Expert Opin Investig Drugs*, 16 (4): 451-465, 2007. DOI: 10.1517/13543784.16.4.451
- Keller C, Kroening S, Zuehlke J, Kunath F, Krueger B, Goppelt-Struebe M:** Distinct mesenchymal alterations in N-cadherin and E-cadherin positive primary renal epithelial cells. *PLoS One*, 7 (8): e43584, 2012. DOI: 10.1371/journal.pone.0043584
- Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ:** N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. *J Cell Biol*, 147 (3): 631-644, 1999. DOI: 10.1083/jcb.147.3.631
- Lundqvist H, Tolmachev V:** Targeting peptides and positron emission tomography. *Biopolymers*, 66 (6): 381-392, 2002. DOI: 10.1002/bip.10348
- Varshney R, Hazari PP, Fernandez P, Schulz J, Allard M, Mishra AK:** <sup>68</sup>Ga-labeled bombesin analogs for receptor-mediated imaging. In: Baum RP, Rösch F (Eds): *Theranostics, Gallium-68, and Other Radionuclides: A Pathway to Personalized Diagnosis and Treatment*. 211-256, Springer, Berlin, 2013.
- Velikyan I:** The diversity of <sup>68</sup>Ga-based imaging agents. In: Baum RP, Rösch F (Eds): *Theranostics, Gallium-68, and Other Radionuclides: A Pathway to Personalized Diagnosis and Treatment*. 101-131, Springer, Berlin, 2013.
- Ozdemir ZO, Karahan M, Karabulut E, Mustafaeva Z:** Characterization of foot-and-mouth disease virus's viral peptides with LC-ESI-MS. *J Chem Soc Pakistan*, 32 (4): 531-536, 2010.
- Ozdemir ZO, Topuzogullari M, Karabulut E, Akdeste ZM:** Characterization and purification of viral peptides synthesized with microwave assisted solid phase method. *IJNES*, 3 (2): 41-44, 2009.
- Palasek SA, Cox ZJ, Collins JM:** Limiting racemization and aspartimide formation in microwave-enhanced Fmoc solid phase peptide synthesis. *J Pept Sci*, 13 (3): 143-148, 2007. DOI: 10.1002/psc.804
- Dubey N, Varshney R, Shukla J, Ganeshpurkar A, Hazari PP, Bandopadhyaya GP, Mishra AK, Trivedi P:** Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog. *Drug Deliv*, 19 (3): 132-142, 2012. DOI: 10.3109/10717544.2012.657718
- Mustafaeva Z:** Synthesis and characterization of antigenic peptide of sheep pox disease. *Kimya Problemleri*, 3, 255-263, 2017.
- Deliloglu Gurhan SI, Akdeste MM, Akdeste Mustafaeva Z, Aynagoz G, Unver G, Unal N, Celik N:** Preparation of synthetic peptide FMD vaccine with newly developed antigen- polymere conjugates be used as immunogen and vaccine in veterinary medicine. *Report of the Europ Comm Cont FMD, Sess Res Gr Stand Tech Com, Çeşme, Izmir, Turkey, FAO/UN Rome*, 17-20 September 2002. www.fao.org/ag/againfo/commissions/docs/research\_group/izmir/App41.pdf
- Kızılbaş K, Mansuroglu B, Derman S, Battal YB, Mustafaeva Z:** Conjugation of BSA protein and VP/AA Copolymers. *IJNES*, 3 (2): 36-40, 2009.
- Sarikaya M, Enginar H:** Radioabeling of L-tyrosine with <sup>131</sup>I and investigation of radiopharmaceutical potential. *AKU J Sci Eng*, 12, 1-9, 2012.
- Baur B, Solbach C, Andreolli E, Winter G, Machulla HJ, Reske SN:** Synthesis, radiolabelling and *in vitro* characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A"-DTPA-DUPA-Pep. *Pharmaceuticals*, 7 (5): 517-529, 2014. DOI: 10.3390/ph7050517
- Pike VW:** PET radiotracers: Crossing the blood-brain barrier and surviving metabolism. *Trends Pharmacol Sci*, 30 (8): 431-440, 2009. DOI: 10.1016/j.tips.2009.05.005
- Waterhouse RN:** Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. *Mol Imaging Biol*, 5 (6): 376-389, 2003. DOI: 10.1016/j.mibio.2003.09.014
- Wilson AA, Jin L, Garcia A, DaSilva JN, Houle S:** An admonition when measuring the lipophilicity of radiotracers using counting techniques. *Appl Radiat Isot*, 54 (2): 203-208, 2001. DOI: 10.1016/S0969-8043(00)00269-4
- Berthod A, Carda-Broch S:** Determination of liquid-liquid partition coefficients by separation methods. *J Chromatogr A*, 1037 (1-2): 3-14, 2004. DOI: 10.1016/j.chroma.2004.01.001
- Rubas W, Cromwell MEM:** The effect of chemical modifications on octanol/water partition (log D) and permeabilities across Caco-2 monolayers. *Adv Drug Deliv Rev*, 23 (1-3): 157-162, 1997. DOI: 10.1016/S0169-409X(96)00433-4
- Leo A, Hansch C, Elkins D:** Partition coefficients and their uses. *Chem Rev*, 71 (6): 525-616, 1971. DOI: 10.1021/cr60274a001
- Wester HJ:** *Pharmaceutical radiochemistry (I) - (Munich Molecular Imaging Handbook Series. Vol. 1. 198-200, Scintomics, Munich, 2010.*
- Ertay T, Unak P, Sencan Eren M, Biber Muftuler FZ, Ozdoğan O, Ulker O, Yesilagac R, Durak H:** A new <sup>99m</sup>Tc labeled peptide: <sup>99m</sup>Tc  $\beta$ -casomorphin 6, biodistribution and imaging studies on rats. *Kafkas*

---

*Univ Vet Fak Derg*, 23 (1): 15-22, 2017. DOI: 10.9775/kvfd.2016.15691

**31. Umbricht CA, Benešová M, Schmid RM, Turler A, Schibli R, van der Meulen NP, Müller C:** <sup>44</sup>Sc-PSMA-617 for radiotheragnostics in tandem with <sup>177</sup>Lu-PSMA-617-preclinical investigations in comparison with <sup>68</sup>Ga-PSMA-11 and <sup>68</sup>Ga-PSMA-617. *EJNMMI Res*, 7 (9): 1-10, 2017. DOI: 10.1186/

s13550-017-0257-4

**32. Klein W, Kördel W, Weiss M, Poremski HJ:** Updating of the OECD test guideline 107 "partition coefficient n-octanol/water": OECD laboratory intercomparison test on the HPLC method. *Chemosphere*, 17 (2): 361-386, 1988. DOI: 10.1016/0045-6535(88)90227-5